UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2017 (June 12, 2017)

PUMA BIOTECHNOLOGY, INC.

(Exact Name of Registrant as Specified in its Charter)

10880 Wilshire Boulevard, Suite 2150

Los Angeles, California 90024

(Address of principal executive offices) (Zip Code)

(424) 248-6500

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Puma Biotechnology, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “2017 Annual Meeting”) on June 12, 2017. At the 2017 Annual Meeting, the Company’s stockholders approved an amendment to the Puma Biotechnology, Inc. 2011 Incentive Award Plan (the “Plan”) to add a limit on compensation payable to non-employee directors (such amendment, the “Director Limit Amendment”). The Director Limit Amendment had been adopted by the Company’s Board of Directors (the “Board”) on April 27, 2017. Additionally, at the 2017 Annual Meeting, the Company’s stockholders approved an amendment to the Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares (such amendment, the “Share Reserve Amendment”). The Share Reserve Amendment had been approved by the Board on April 27, 2017, subject to receiving stockholder approval at the 2017 Annual Meeting.

The terms and conditions of the Director Limit Amendment are described in the section entitled “Proposal 3 Approval of Third Amendment to the Puma Biotechnology, Inc. 2011 Incentive Award Plan” (the “Director Limit Stockholder Proposal”) and the terms and conditions of the Share Reserve Amendment are described in the section entitled “Proposal 4 Approval of Fourth Amendment to the Puma Biotechnology, Inc. 2011 Incentive Award Plan” (the “Share Reserve Stockholder Proposal”) in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2017. The descriptions of the terms and conditions of the Director Limit Amendment in the Director Limit Stockholder Proposal and the terms and conditions of the Share Reserve Amendment in the Share Reserve Stockholder Proposal do not purport to be complete descriptions of the Director Limit Amendment and the Share Reserve Amendment and are qualified in their entirety by reference to the complete texts of the Director Limit Amendment and the Share Reserve Amendment, copies of which are filed as Exhibit 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

(a) The 2017 Annual Meeting was held at 1:00 p.m. Pacific Daylight Time on June 12, 2017 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

(b) The following proposals were voted upon at the 2017 Annual Meeting and the final voting results with respect to each such proposal are set forth below:

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX